Disruption of Supply

GlaxoSmithKline PLC
04 March 2005


         GSK Announces Disruption of Supply for Paxil CR and Avandamet

March 4, 2005 - GlaxoSmithKline (GSK) said today that the US Food and Drug
Administration has halted distribution of supplies of two of its medicines due
to manufacturing issues: Avandamet (rosiglitazone  maleate / metformin
hydrochloride) tablets, used to treat type 2 diabetes, and Paxil CR (paroxetine
hydrochloride controlled release) tablets, a treatment for depression and
several anxiety disorders.

The FDA action relates to all strengths of Paxil CR (12.5 mg, 25 mg, and 37.5
mg) as well as Avandamet (1 mg, 2 mg, and 4 mg).  In the short term, it is
expected that the FDA action will result in a shortage of patient supplies for
both of these medicines.

GSK believes that the manufacturing issues do not pose a health risk to
patients.  GSK agrees with the FDA that patients who use these two medicines
should continue taking their tablets and talk with their healthcare provider if
they have questions.

The company is working with the FDA to resolve these issues as quickly as
possible.

S M Bicknell
Company Secretary

4 March 2005

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For company information
visit www.gsk.com.

________________________________________________________________________________

                                                                                               
Enquiries:  UK Media                         Philip Thomson      [phone]
                                             David Mawdsley      [phone]
                                             Chris Hunter-Ward   [phone]

            US Media                         Nancy Pekarek       [phone]
                                             Mary Anne Rhyne     [phone]
                                             Patricia Seif       [phone]

            European Analyst / Investor      Duncan Learmouth    [phone]
                                             Anita Kidgell       [phone]

            US Analyst / Investor            Frank Murdolo       [phone]
                                             Tom Curry           [phone]

________________________________________________________________________________


                      This information is provided by RNS
            The company news service from the London Stock Exchange